Trials / Completed
CompletedNCT00329810
Effect on Cognitive Function of a Treatment With Aripiprazole
A Prospective, Multicenter, Open-Label Study to Evaluate the Effectiveness and the Effect on Cognitive Function of a Treatment With Aripiprazole in a Board Range of Schizophrenic Patients
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 500 (actual)
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the effectiveness of Aripiprazole after 12 weeks of therapy for Schizophrenic patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aripiprazole | Tablets, oral, 15 mg, once daily, 12 weeks. |
Timeline
- Start date
- 2005-03-01
- Primary completion
- 2006-03-01
- Completion
- 2006-03-01
- First posted
- 2006-05-25
- Last updated
- 2013-11-08
Source: ClinicalTrials.gov record NCT00329810. Inclusion in this directory is not an endorsement.